Related Experiment Video
Updated: Nov 17, 2025

Generic Protocol for Optimization of Heterologous Protein Production Using Automated Microbioreactor Technology
Published on: December 15, 2017
Are oral rehydration solutions optimized for treating diarrhea?
Samuel N Cheuvront1,2, Robert W Kenefick2, Laura Luque2
1Sports Science Synergy, Franklin, USA.
Background:
A historical turning point occurred in the treatment of diarrhea when it was discovered that glucose could enhance intestinal sodium and water absorption. Adding glucose to salt water (oral rehydration solution, ORS) more efficiently replaced intestinal water and salt losses.
Aim:
Provide a novel hypothesis to explain why mainstream use of ORS has been strongly recommended, but weakly adopted.
Methods:
Traditional (absorptive) and novel (secretory) physiological functions of glucose in an ORS were reviewed.
Results:
Small amounts of glucose can stimulate both intestinal absorption and secretion. Glucose can exacerbate a net secretory state and may aggravate pathogen-induced diarrhea, particularly for pathogens that affect glucose transport.
Conclusion:
A hypothesis is made to explain why glucose-based ORS does not appreciably reduce diarrheal stool volume and why modern food science initiatives should focus on ORS formulations that replace water and electrolytes while also reducing stool volume and duration of diarrhea.
More Related Videos
06:59A Novel Approach for the Administration of Medications and Fluids in Emergency Scenarios and Settings
Published on: November 9, 2016
03:25Author Spotlight: Exploring Non-Pharmacological Therapies for Chronic Respiratory Diseases — Linking Intestinal Microbiome Insights to COPD Treatment
Published on: December 27, 2024
Related Concept Videos
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
Dosage Regimens: Designs and Approaches
Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents
Adsorbents...
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Acute Kidney Injury V: Interprofessional Care
Bioavailability Enhancement: Drug Solubility Enhancement